PDE4A and fragile X syndrome: The initial findings supporting PDE4 as a therapeutic target in FXS come from work in Drosophila and later mouse40-42 and most recently a Phase 2 clinical trial.15 PDE10 is however a target of FMRP43 and as a result levels are elevated in FXS.